The aim of this study was to evaluate the therapeutic effectiveness and safety of an association of membranous proteoglycans of Klebsiella pneumoniae and bacterial ribosomes of Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae in patients suffering from recurrent respiratory infections. We have evaluated, in double blind randomized versus placebo study, 64 subjects affected by chronic bronchitis, with age ranging between 27 and 70 years, of both sexes. The drug was administered according to the following protocol: 1 tablet daily for 4 days in a week for 3 weeks and 1 tablet daily for 4 days in a month for 5 months. A significant reduction in infectious recurrences was obtained in all patients treated with the active drug. Our results suggest that the association of bacterial ribosomes and membranous proteoglycans of Klebsiella pneumoniae is effective in reducing recurrent respiratory infections.
|Translated title of the contribution||Infectious exacerbations of chronic pulmonary diseases. Therapeutic effectiveness of immunomodulants|
|Number of pages||6|
|Publication status||Published - 1995|
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine